期刊文献+

高效液相色谱法测定阿哌沙班中的有关物质 被引量:5

Determination of related substances in apixaban by HPLC
下载PDF
导出
摘要 目的建立高效液相色谱法定量测定阿哌沙班中有关物质。方法采用加校正因子的主成分自身对照法,对阿哌沙班中有关物质进行定量分析,并对该方法进行了方法学验证。结果杂质1、杂质2、杂质3、杂质4、杂质5及阿哌沙班的定量限分别为38.0、75.0、57.0、49.0、58.0和52.0μg·L^(-1);检测限分别为11.0、22.0、17.0、15.0、18.0和16.0μg·L^(-1)。各杂质的线性关系良好(r≥0.999),样品低、中、高三个水平的回收率均在90.0%~108.0%内,RSD≤4.0%。样品中杂质1含量质量分数为0.29%,最大未知单杂质含量质量分数为0.23‰,总杂质含量质量分数为0.31%。结论该方法可用于测定阿哌沙班中有关物质。 Objective To establish an HPLC method for the determination of related substances in apixaban. Method The self contrast and correction factor method was established to determine the related substances in apixaban simultaneously. Methods validation was also performed. Results The limits of quantitation for impurity 1 ,impurity 2,impurity 3,impurity 4,impurity 5 and apixaban were 38.0,75.0,57.0,49.0,58.0 and 52. 0 μg·L^-1 respectively. And the limits of detection for impurities and apixaban were 11.0,22. 0, 17.0,15.0,18.0 and 16.0 μg·L^-1 respectively. There was good linear relationship between response values and contents in the experimental concentration range of five impurities and apixaban ( r ≥0. 999 ). The recov- ery ranged from 90.0% to 108.0% with RSD ≤4.0%. The content of impurity 1 and unspecified impurity in the sample was 0. 29% and 0. 23‰, and the total impurities was 0. 31%. Conclusions This method can be used to determine the related substances presented in apixaban.
出处 《沈阳药科大学学报》 CAS CSCD 北大核心 2017年第1期37-42,共6页 Journal of Shenyang Pharmaceutical University
关键词 阿哌沙班 有关物质 校正因子 高效液相色谱法 apixaban related substance correction factor HPLC
  • 相关文献

参考文献4

二级参考文献26

  • 1中国药典[S].2010年版.二部.附录ⅨJ. 被引量:345
  • 2Piovella F, Wang CJ, Lu H, et al. Deep-vein thrombosis ratesaftermajor orthopedic surgery in Asia. An ep idemiological studybased on postoperative screening with centrally adjudicatedbilateral venography [ J]. J Thromb Haemost, 2005,3 : 2664 -2670. 被引量:1
  • 3Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venousthromboembolism. American College of Chest Physicians evidence-based clinical practice guidelines ( 8th edn) [ J]. Chest, 2008 ,133: 381S-453S. 被引量:1
  • 4Donald JP, Michael JO, Stephanie K, et al. Discovery of 1-(4-Methoxyphenyl) -7-oxo-6-(4-( 2-oxopiperidin-l -yl) phenyl) A,5,6,7-tetrahydro-l H-pyrazolo [ 3, 4-c ] pyridine-3 -carboxamide(apixaban, BMS-562247 ),a highly potent, selective,efficacious, and orally bioavmlable inhibitor of blood coagulationfactor Xa [ J ]. J Med Chem, 2007,50: 5339 -5356. 被引量:1
  • 5Charles F, Sunil N, Jessie Wang, et al. Safety, pharmaco- kinetics and pharmaeodynamics of multiple oral doses of apixaban, a factor X a inhibitor, in healthy subjects[J]. British Journal of Clinical Pharmacology, 2013,76 (5) : 776. 被引量:1
  • 6Yang L,Ge W, Yu F, et al. Impact of VKORC1 gene polymor phism on inter-individual and interethnic warfarin dosage re- quirement-a systematic review and meta analysis [J]. Thromb Res,2010,125(4) : el 59-e1 66. 被引量:1
  • 7Miao L, Yang J, Huang C, et al. Contribution of age, body weight and CYP2C9 and VKORC1 genotype to the anticoagu lant response to warfarim proposal for a new dosing regimen in Chinese patients [ J ]. Eur J Clin Pharmacol, 2007, 63 ( 12 ) : 1135-1141. 被引量:1
  • 8Wen MS,Lee M,Chen JJ,et al. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 geno- types [J]. Clin Pharamaeol Ther, 2008,84 ( 1 ) : 83-89. 被引量:1
  • 9Ohno M,Yamamoto A, Ono A, et al. Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients[J]. Eur J Clin Pharamacol,2009,65(11) : 1097-1103. 被引量:1
  • 10Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmaeogenetic data[J]. N En- gl J Med,2009,360(8) :753-764. 被引量:1

共引文献33

同被引文献29

引证文献5

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部